Robert Andrew Stockley

Robert Andrew Stockley

Auto-generated profile, based on publicly available information

Robert Andrew Stockley

Department of Inflammation and Ageing, University of Birmingham, Birmingham, UK

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2006 in Thorax
Verified
Journal Article
Open access
PDF file
ESE Sapey
E Sapey
RSR A Stockley
R A Stockley
Exacerbations of COPD are thought to be caused by complex interactions between the host, bacteria, viruses, and environmental pollution. These factors increase the inflammatory burden in the lower airways, overwhelming the protective anti-inflammatory defences leading to tissue damage. Frequent exacerbations are associated with increased morbidity and mortality, a faster decline in lung function, and poorer health status, so prevention or optimal treatment of exacerbations is a global priority. In order to evolve new treatment strategies there has been great interest in the aetiology and pathophysiology of exacerbations, but progress has been hindered by the heterogeneous nature of these episodes, vague definitions of an exacerbation, and poor stratification of known confounding factors when interpreting results. We review how an exacerbation should be defined, its inflammatory basis, and the importance of exacerbations on disease progression. Important aetiologies, with their potential underlying mechanisms, are discussed and the significance of each aetiology is considered.

30 November 2017 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
MMMarc Miravitlles
Marc Miravitlles
ADAsger Dirksen
Asger Dirksen
IFIlaria Ferrarotti
Ilaria Ferrarotti
VKVladimir Koblizek
Vladimir Koblizek
PLPeter Lange
Peter Lange
RSRobert A. Stockley
Robert A. Stockley
α1-antitrypsin deficiency (AATD) is the most common hereditary disorder in adults. It is associated with an increased risk of developing pulmonary emphysema and liver disease. The pulmonary emphysema in AATD is strongly linked to smoking, but even a proportion of never-smokers develop progressive lung disease. A large proportion of individuals affected remain undiagnosed and therefore without access to appropriate care and treatment.The most recent international statement on AATD was published by the American Thoracic Society and the European Respiratory Society in 2003. Since then there has been a continuous development of novel, more accurate and less expensive genetic diagnostic methods. Furthermore, new outcome parameters have been developed and validated for use in clinical trials and a new series of observational and randomised clinical trials have provided more evidence concerning the efficacy and safety of augmentation therapy, the only specific treatment available for the pulmonary disease associated with AATD.As AATD is a rare disease, it is crucial to organise national and international registries and collect information prospectively about the natural history of the disease. Management of AATD patients must be supervised by national or regional expert centres and inequalities in access to therapies across Europe should be addressed.

13 July 2010 in Thorax
Verified
Journal Article
Closed access
PDF file
NSNicola J Sinden
Nicola J Sinden
RSR. A. Stockley
R. A. Stockley
Chronic obstructive pulmonary disease (COPD) is characterised by an inflammatory response by the lungs to inhaled substances such as cigarette smoking and air pollutants. In addition to the pulmonary features of COPD, several systemic effects have been recognised even after controlling for common aetiological factors such as smoking or steroid use. These include skeletal muscle dysfunction, cardiovascular disease, osteoporosis and diabetes. Individuals with COPD have significantly raised levels of several circulating inflammatory markers indicating the presence of systemic inflammation. This raises the issue of cause and effect. The role of tumour necrosis factor α in COPD is thought to be central to both lung and systemic inflammation and has been implicated in skeletal muscle dysfunction, osteoporosis and type 2 diabetes. It has been hypothesised that inflammation in the lung results in ‘overspill’ into the circulation causing systemic inflammation. There is supportive evidence that protein movement can occur from the lung surface to the systemic circulation. Evidence from inhaled substances such as air pollutants and cigarette smoke has demonstrated a temporal link between the inflammatory process in the lung and systemic inflammation. Also, studies have shown alterations in circulating inflammatory cells in patients with COPD compared with controls which may reflect the effects of inflammatory mediators (derived from the lung) on circulating cells or the bone marrow. This paper considers the concept of ‘overspill’ in depth, reviews the current evidence and highlights problems in generating direct evidence to support or refute this concept.

1 May 2002 in Chest
Verified
Journal Article
Closed access
RSRobert A. Stockley
Robert A. Stockley

1 April 2013 in Respiratory Medicine
Verified
Journal Article
Closed access
RSRobert Stockley
Robert Stockley
ASAnthony De Soyza
Anthony De Soyza
KGKulasiri Gunawardena
Kulasiri Gunawardena
JPJohn Perrett
John Perrett
KFKristina Forsman-Semb
Kristina Forsman-Semb
NSNoel Snell
Noel Snell

26 January 2006 in Respiratory Research
Verified
Journal Article
Open access
PDF file
Judit E PongraczJudit E Pongracz
Judit E Pongracz
RSRobert A Stockley
Robert A Stockley
There are several signalling pathways involved in lung organogenesis including Notch, TGFβ /BMP, Sonic hedgehog (Shh), FGF, EGF, and Wnt. Despite the widely acknowledged significance of Wnt signalling in embryonic lung development, the role of different Wnt pathways in lung pathologies has been slow to emerge.In this review, we will present a synopsis of current Wnt research with particular attention paid to the role of Wnt signals in lung development and in pulmonary diseases.